logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Trick or Trade

The Time Has Come for This Small Biotech Firm to Grow and Thrive

CytomX Therapeutics CytomX ( CTMX ) is a clinical-stage oncology-focused biopharmaceutical company developing a novel class of investigational antibody therapeutics based on the firm’s Probody® technology platform for cancer treatments. CytomX’s Probody therapeutics remain inactive until they are activated by proteases...

Read More

April 30, 2020

0

Gain Therapeutics: A Biotech with Promising Treatments for Neurodegenerative Diseases and a Note from Prohost Biotech

Gain Therapeutics Inc in the News Gain Therapeutics, Inc. ( GANX ) announced today topline data from its  study conducted at the University of Maryland School of Medicine (UMSOM). The study, evaluating two lead Structurally Targeted Allosteric Regulators ( STARs...

Read More

September 8, 2021

0

Why Jounce Therapeutics Stock is Outperforming Today

Jounce Therapeutics Jounce Therapeutics ( JNCE ) is a clinical-stage immunotherapy company developing therapies enabling the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce has ongoing multiple development stage programs while simultaneously...

Read More

September 14, 2021

0

The Time Has Come to Present Mirum Pharmaceuticals Inc

Mirum Pharmaceuticals Inc Mirum Pharmaceuticals Inc ( MIRM ) is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Maralixibat, is Mirum Pharmaceuticals lead product candidate. The product...

Read More

September 27, 2021

0

The FDA Approval of Biogen's Alzheimer's Disease Drug and How Cassava Sciences Alzheimer's Disease Drug Differs

Biogen Product Adulelm Approved for Alzheimer's Disease The latest news regarding Alzheimer’s disease is that of the FDA’s approval of Biogen Inc's ( BIIB ) Alzheimer disease product Adulelm (aducanumab). Although the approval seemed to be great news for Biogen...

Read More

June 12, 2021

0

Agenus Strategic Decision to Withdraw the BLA for Balsitilimab

Agenus to Withdraw BLA for Balstilimab Agenus ( AGEN ) announced a strategic decision to withdraw its Biologics License Application ( BLA ) for balstilimab, its PD-1 inhibitor. The firm stated that its decision will not change the development plans...

Read More

October 22, 2021

0

There Is A Lot More To Say About the COVID-19 Vaccines

Pfizer and BioNTech Vaccines Were Granted FDA Fast Track Designation Against SARS-CoV-2 (COVID-19) A large Phase 2b/3 safety and efficacy study may begin as early as July 2020 Pfizer ( PFE ) and BioNTech ( BNTX ) announced that two...

Read More

July 13, 2020

0

Encouraging News from Hoth Therapeutics and Kintor Pharmaceutical Ltd About Treating Acne and Alopecia

Hoth Therapeutics Hoth Therapeutics ( HOTH ) announced that its product, HT-003, has yielded positive results in an in vivo  acne therapeutic  model. The model showed that HT-003 reduces the expression of toll-like receptor 2 ( TLR2 ), which happens...

Read More

July 14, 2021

0

Could Arbutus Biopharma's Patent Harm Moderna?

Arbutus Biopharma and Moderna's Patent Challenge Arbutus Biopharma ( ABUS ) is a publicly-traded biopharmaceutical company dedicated to discovering and developing a cure for patients suffering from chronic hepatitis B infection. The stock has been in the Aggressive Table of...

Read More

July 24, 2020

0

Edesa Biotech Stock Price Soared. Will It Continue to Rise?

Edesa Biotech Filed an IND for EB05 Edesa Biotech ( EDSA ) , a clinical-stage biopharmaceutical company, has filed an investigational new drug ( IND ) application with the U.S. FDA for the initiation of a Phase 2/3 clinical study...

Read More

July 30, 2020

0

  • Previous
  • 1
  • 2
  • ...
  • 5
  • 6
  • 7
  • ...
  • 16
  • 17
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy